Advertisement

Current Hematologic Malignancy Reports

, Volume 13, Issue 6, pp 426–434 | Cite as

Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies

  • Imo J. Akpan
  • Afaf E. G. Osman
  • Michael W. Drazer
  • Lucy A. GodleyEmail author
Acute Myeloid Leukemias (H Erba, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Acute Myeloid Leukemias

Abstract

Purpose of Review

To review the diagnosis of individuals with hereditary hematopoietic malignancies (HHMs) that predispose to myelodysplastic syndrome and acute myeloid leukemia, barriers to HHM diagnosis, and unaddressed questions and controversies within the HHM field.

Recent Findings

Pathogenic germline mutations in approximately a dozen genes predispose to HHMs, and many more genes are likely to be involved. Many of these HHM genes have only been identified recently. HHM phenotypes are diverse, but may be categorized as “purely” myeloid syndromes, syndromes with abnormal platelet number/function, and HHMs with additional organ system involvement. A number of questions remain unanswered in this emerging field, including the ideal diagnostic approach for patients at risk for HHMs, the optimal surveillance of unaffected carriers, and how to personalize care for individuals with HHMs.

Summary

The field of HHMs is evolving rapidly. Ongoing research in this area will eventually inform the care of patients with both somatic and hereditary cancer syndromes, but much work remains to be done.

Keywords

Inherited leukemia Familial leukemia Hereditary leukemia 

Notes

Compliance with Ethical Standards

Conflict of Interest

Lucy Godley reports other from UpToDate, Inc., outside of the submitted work. Imo J. Akpan, Afaf Osman, and Michael W. Drazer declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Gunz FW, Gunz JP, Veale AM, Chapman CJ, Houston IB. Familial leukaemia: a study of 909 families. Scand J Haematol. 1975;15(2):117–31.CrossRefGoogle Scholar
  2. 2.
    Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23(2):166–75.  https://doi.org/10.1038/13793.CrossRefPubMedGoogle Scholar
  3. 3.
    •• Drazer MW, Feurstein S, West AH, Jones MF, Churpek JE, Godley LA. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood. 2016;128(14):1800–13.  https://doi.org/10.1182/blood-2016-05-670240 This is a succinct description of our clinical approach to the evaluation and management of individuals thought to have germline susceptibility to myeloid malignancies. CrossRefGoogle Scholar
  4. 4.
    Tawana K, Drazer MW, Churpek JE. Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet? Leukemia. 2018;32:1482–92.  https://doi.org/10.1038/s41375-018-0051-y.CrossRefPubMedGoogle Scholar
  5. 5.
    •• Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, et al. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(1):60–87 These clinical guidelines are among the first to include testing for germline predisposition to myeloid malignancies for MDS patients. CrossRefGoogle Scholar
  6. 6.
    •• Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47.  https://doi.org/10.1182/blood-2016-08-733196 These clinical guidelines are among the first to include testing for germline predisposition to myeloid malignancies for AML patients. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    •• Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.  https://doi.org/10.1182/blood-2016-03-643544 The WHO revision for myeloid leukemias included a provisional category for germline susceptibility testing for the first time. CrossRefPubMedGoogle Scholar
  8. 8.
    Topaz O, Indelman M, Chefetz I, Geiger D, Metzker A, Altschuler Y, et al. A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis. Am J Hum Genet. 2006;79(4):759–64.  https://doi.org/10.1086/508069.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    • Nagamachi A, Matsui H, Asou H, Ozaki Y, Aki D, Kanai A, et al. Haploinsufficiency of SAMD9L, an endosome fusion facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy 7. Cancer Cell. 2013;24(3):305–17.  https://doi.org/10.1016/j.ccr.2013.08.011 This is the first published description of SAMD9L mutations causing myeloid malignancies in mice. CrossRefPubMedGoogle Scholar
  10. 10.
    Tawana K, Fitzgibbon J. Inherited DDX41 mutations: 11 genes and counting. Blood. 2016;127(8):960–1.  https://doi.org/10.1182/blood-2016-01-690909.CrossRefPubMedGoogle Scholar
  11. 11.
    Carapito R, Konantz M, Paillard C, Miao Z, Pichot A, Leduc MS, et al. Mutations in signal recognition particle SRP54 cause syndromic neutropenia with Shwachman-Diamond-like features. J Clin Invest. 2017;127(11):4090–103.  https://doi.org/10.1172/JCI92876.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Pecci A. Diagnosis and treatment of inherited thrombocytopenias. Clin Genet. 2016;89(2):141–53.  https://doi.org/10.1111/cge.12603.CrossRefPubMedGoogle Scholar
  13. 13.
    • Zhang MY, Churpek JE, Keel SB, Walsh T, Lee MK, Loeb KR, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet. 2015;47(2):180–5.  https://doi.org/10.1038/ng.3177 This is the first published description of germline ETV6 mutations. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savoia A, et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015;47(5):535–8.  https://doi.org/10.1038/ng.3253.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Topka S, Vijai J, Walsh MF, Jacobs L, Maria A, Villano D, et al. Germline ETV6 mutations confer susceptibility to acute lymphoblastic leukemia and thrombocytopenia. PLoS Genet. 2015;11(6):e1005262.  https://doi.org/10.1371/journal.pgen.1005262.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Fiore M, Saut N, Alessi MC, Viallard JF. Successful use of eltrombopag for surgical preparation in a patient with ANKRD26-related thrombocytopenia. Platelets. 2016;27:1–2.  https://doi.org/10.1080/09537104.2016.1190446.CrossRefGoogle Scholar
  17. 17.
    Feurstein S, Drazer MW, Godley LA. Genetic predisposition to leukemia and other hematologic malignancies. Semin Oncol. 2016;43(5):598–608.  https://doi.org/10.1053/j.seminoncol.2016.10.003.CrossRefPubMedGoogle Scholar
  18. 18.
    Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004;351(23):2403–7.  https://doi.org/10.1056/NEJMoa041331.CrossRefPubMedGoogle Scholar
  19. 19.
    Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol. 2008;26(31):5088–93.  https://doi.org/10.1200/JCO.2008.16.5563.CrossRefPubMedGoogle Scholar
  20. 20.
    Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck CA, Wouters BJ, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117(8):2469–75.  https://doi.org/10.1182/blood-2010-09-307280.CrossRefPubMedGoogle Scholar
  21. 21.
    • Tawana K, Wang J, Renneville A, Bödör C, Hills R, Loveday C, et al. Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood. 2015;126(10):1214–23.  https://doi.org/10.1182/blood-2015-05-647172 This publication established that patients with germline CEBPA mutations develop multiple primary myeloid malignancies rather than relapses of a single disease. CrossRefPubMedGoogle Scholar
  22. 22.
    Tawana K, Rio-Machin A, Preudhomme C, Fitzgibbon J. Familial CEBPA-mutated acute myeloid leukemia. Semin Hematol. 2017;54(2):87–93.  https://doi.org/10.1053/j.seminhematol.2017.04.001.CrossRefPubMedGoogle Scholar
  23. 23.
    • Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27(5):658–70.  https://doi.org/10.1016/j.ccell.2015.03.017 This is the first published description of germline DDX41 mutations. CrossRefPubMedGoogle Scholar
  24. 24.
    Lewinsohn M, Brown AL, Weinel LM, Phung C, Rafidi G, Lee MK, et al. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood. 2016;127(8):1017–23.  https://doi.org/10.1182/blood-2015-10-676098.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Cheah JJC, Hahn CN, Hiwase DK, Scott HS, Brown AL. Myeloid neoplasms with germline DDX41 mutation. Int J Hematol. 2017;106(2):163–74.  https://doi.org/10.1007/s12185-017-2260-y.CrossRefPubMedGoogle Scholar
  26. 26.
    Drazer MW, Kadri S, Sukhanova M, Patil SA, West AH, Feurstein S, et al. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Adv. 2018;2(2):146–50.  https://doi.org/10.1182/bloodadvances.2017013037.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Saliba J, Saint-Martin C, Di Stefano A, Lenglet G, Marty C, Keren B, et al. Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nat Genet. 2015;47(10):1131–40.  https://doi.org/10.1038/ng.3380.CrossRefPubMedGoogle Scholar
  28. 28.
    Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 2011;43(10):1012–7.  https://doi.org/10.1038/ng.913.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ostergaard P, Simpson MA, Connell FC, Steward CG, Brice G, Woollard WJ, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet. 2011;43(10):929–31.  https://doi.org/10.1038/ng.923.CrossRefPubMedGoogle Scholar
  30. 30.
    Hirabayashi S, Wlodarski MW, Kozyra E, Niemeyer CM. Heterogeneity of GATA2-related myeloid neoplasms. Int J Hematol. 2017;106(2):175–82.  https://doi.org/10.1007/s12185-017-2285-2.CrossRefPubMedGoogle Scholar
  31. 31.
    • Wlodarski MW, Hirabayashi S, Pastor V, Starý J, Hasle H, Masetti R, et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood. 2016;127(11):1387–97.  https://doi.org/10.1182/blood-2015-09-669937 This publication established that germline GATA2 mutations are common in young people diagnosed with MDS with monosomy 7. CrossRefPubMedGoogle Scholar
  32. 32.
    Cuellar-Rodriguez J, Gea-Banacloche J, Freeman AF, Hsu AP, Zerbe CS, Calvo KR, et al. Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood. 2011;118(13):3715–20.  https://doi.org/10.1182/blood-2011-06-365049.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Grossman J, Cuellar-Rodriguez J, Gea-Banacloche J, Zerbe C, Calvo K, Hughes T, et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Biol Blood Marrow Transplant. 2014;20(12):1940–8.  https://doi.org/10.1016/j.bbmt.2014.08.004.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014;123(6):809–21.  https://doi.org/10.1182/blood-2013-07-515528.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the telomeropathies. Blood. 2014;124(18):2775–83.  https://doi.org/10.1182/blood-2014-05-526285.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Alter BP. Inherited bone marrow failure syndromes: considerations pre- and posttransplant. Blood. 2017;130(21):2257–64.  https://doi.org/10.1182/blood-2017-05-781799.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    West AH, Churpek JE. Old and new tools in the clinical diagnosis of inherited bone marrow failure syndromes. Hematol Am Soc Hematol Educ Program. 2017;2017(1):79–87.  https://doi.org/10.1182/asheducation-2017.1.79.CrossRefGoogle Scholar
  38. 38.
    Dokal I, Vulliamy T. Inherited bone marrow failure syndromes. Haematologica. 2010;95(8):1236–40.  https://doi.org/10.3324/haematol.2010.025619.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Kirwan M, Walne AJ, Plagnol V, Velangi M, Ho A, Hossain U, et al. Exome sequencing identifies autosomal-dominant SRP72 mutations associated with familial aplasia and myelodysplasia. Am J Hum Genet. 2012;90(5):888–92.  https://doi.org/10.1016/j.ajhg.2012.03.020.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    • Narumi S, Amano N, Ishii T, Katsumata N, Muroya K, Adachi M, et al. SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. Nat Genet. 2016;48(7):792–7.  https://doi.org/10.1038/ng.3569 This is the first published description of germline SAMD9 mutations. CrossRefPubMedGoogle Scholar
  41. 41.
    • Chen DH, Below JE, Shimamura A, Keel SB, Matsushita M, Wolff J, et al. Ataxia-pancytopenia syndrome is caused by missense mutations in SAMD9L. Am J Hum Genet. 2016;98(6):1146–58.  https://doi.org/10.1016/j.ajhg.2016.04.009 This is the first published decription of germline SAMD9L mutations. CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Tesi B, Davidsson J, Voss M, Rahikkala E, Holmes TD, Chiang SCC, et al. Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. Blood. 2017;129(16):2266–79.  https://doi.org/10.1182/blood-2016-10-743302.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Davidsson J, Puschmann A, Tedgard U, Bryder D, Nilsson L, Cammenga J. SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies. Leukemia. 2018;32(5):1106–15.  https://doi.org/10.1038/s41375-018-0074-4.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    • Sanders MA, Chew E, Flensburg C, Zeilemaker A, Miller SE, Al Hinai AS, et al. MBD4 guards against methylation damage and germline deficiency predisposes to clonal hematopoiesis and early-onset AML. Blood. 2018.  https://doi.org/10.1182/blood-2018-05-852566 This is the first published decription of germline MBD4 mutations.
  45. 45.
    Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med. 2017;377(15):1409–12.  https://doi.org/10.1056/NEJMp1709968.CrossRefPubMedGoogle Scholar
  46. 46.
    Keel SB, Scott A, Sanchez-Bonilla M, Ho PA, Gulsuner S, Pritchard CC, et al. Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients. Haematologica. 2016;101:1343–50.  https://doi.org/10.3324/haematol.2016.149476.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Churpek JE, Nickels E, Marquez R, Rojek K, Liu B, Lorenz R, et al. Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood. 2012;120(26):5247–9.  https://doi.org/10.1182/blood-2012-09-457945.CrossRefPubMedGoogle Scholar
  48. 48.
    Rojek K, Nickels E, Neistadt B, Marquez R, Wickrema A, Artz A, et al. Identifying inherited and acquired genetic factors involved in poor stem cell mobilization and donor-derived malignancy. Biol Blood Marrow Transplant. 2016;22(11):2100–3.  https://doi.org/10.1016/j.bbmt.2016.08.002.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(7):926–57.  https://doi.org/10.6004/jnccn.2017.0116.CrossRefGoogle Scholar
  50. 50.
    He J, Abdel-Wahab O, Nahas MK, Wang K, Rampal RK, Intlekofer AM, et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood. 2016;127(24):3004–14.  https://doi.org/10.1182/blood-2015-08-664649.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Guidugli L, Johnson AK, Alkorta-Aranburu G, Nelakuditi V, Arndt K, Churpek JE, et al. Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes. Leukemia. 2017;31(5):1226–9.  https://doi.org/10.1038/leu.2017.28.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Kadri S, Long BC, Mujacic I, Zhen CJ, Wurst MN, Sharma S, et al. Clinical validation of a next-generation sequencing genomic oncology panel via cross-platform benchmarking against established amplicon sequencing assays. J Mol Diagn. 2017;19(1):43–56.  https://doi.org/10.1016/j.jmoldx.2016.07.012.CrossRefPubMedGoogle Scholar
  53. 53.
    Gross M, Hanenberg H, Lobitz S, Friedl R, Herterich S, Dietrich R, et al. Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction. Cytogenet Genome Res. 2002;98(2–3):126–35.  https://doi.org/10.1159/000069805.CrossRefPubMedGoogle Scholar
  54. 54.
    Godley LA. Inherited predisposition to acute myeloid leukemia. Semin Hematol. 2014;51(4):306–21.  https://doi.org/10.1053/j.seminhematol.2014.08.001.CrossRefPubMedGoogle Scholar
  55. 55.
    Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, et al. Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood. 2018;131(21):2402–5.  https://doi.org/10.1182/blood-2018-01-827881.CrossRefPubMedGoogle Scholar
  56. 56.
    West RR, Hsu AP, Holland SM, Cuellar-Rodriguez J, Hickstein DD. Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation. Haematologica. 2014;99(2):276–81.  https://doi.org/10.3324/haematol.2013.090217.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Imo J. Akpan
    • 1
  • Afaf E. G. Osman
    • 1
  • Michael W. Drazer
    • 1
    • 2
  • Lucy A. Godley
    • 1
    • 2
    Email author
  1. 1.Section of Hematology/Oncology, Department of Medicine, The University of Chicago Comprehensive Cancer CenterThe University of ChicagoChicagoUSA
  2. 2.Department of Human GeneticsThe University of ChicagoChicagoUSA

Personalised recommendations